Equity Profile
Pre-Earnings Brief
Kiniksa Pharmaceuticals International, plc (KNSA) is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. Operating in the health care sector, Kiniksa's work is crucial as it aims to address unmet medical needs through its pipeline of drug candidates.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will show how well Kiniksa is managing its costs and generating income.
Revenue Growth
Although specific revenue figures are not available, growth in revenue is essential for assessing the company's market performance and product acceptance.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
50%
Avg EPS Surprise
-110.97%
Avg Stock Reaction
+6.62%
In Q1-2026, Kiniksa reported an EPS of $0.27, significantly beating expectations of $0.18, which led to a 23.48% increase in stock price the following day. However, revenue figures were not disclosed.
Management Promises & Guidance
Overall, expectations are mixed as Kiniksa has shown strong EPS performance in the past but lacks detailed revenue guidance. Investors will be watching closely to see if the positive trend continues.
Bull Case
If Kiniksa continues to exceed EPS expectations and provides positive updates on its drug pipeline, it could lead to significant stock appreciation.
Bear Case
Conversely, if the company fails to meet earnings expectations or provides disappointing insights into its revenue growth, it could lead to a decline in stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of profitability and will show how well Kiniksa is managing its costs and generating income.
Revenue Growth
N/AAlthough specific revenue figures are not available, growth in revenue is essential for assessing the company's market performance and product acceptance.
Expectations
The print will turn on these two things.
Q1
What will the EPS be for Q2-2026?
Given the company's recent performance, this figure will be crucial for determining investor sentiment and stock movement.
Q2
What updates can be provided regarding revenue growth and product pipeline?
Insights into revenue and the status of drug candidates will be key for assessing the company's future prospects.
Edge
Why consensus could be wrong
The Street may be underestimating Kiniksa's ability to sustain its recent EPS growth, given the strong surprise in the last quarter.
Supporting Evidence
Kiniksa has a history of beating EPS estimates, which could indicate a trend that continues this quarter.
The options market is pricing in a larger move than historical averages suggest, indicating heightened expectations.
Key Risk
If EPS comes in below $0.18, it could significantly shift market sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter's performance hinges on Kiniksa's ability to maintain or exceed its recent earnings momentum while addressing revenue growth.
Bull Confirmed If
An EPS of $0.30 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $0.18 would confirm the bear case, suggesting potential issues in profitability.
Pre-Earnings Positioning
Implied Move
±26.81%
Historical Avg
±13.3%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±25.2% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
69.7%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
n=30Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$388,834.32
8,328 sh
2 insiders
Net
$388,834.32
Net selling
Most Active Insiders· 2 open-market trades
$309,321.25
Net selling
$79,513.07
Net selling
Recent Transactions
Apr 9, 2026 · @ $46.69
6,625 sh
$309,321.25
Apr 9, 2026 · @ $46.69
1,703 sh
$79,513.07
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming positive market sentiment.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss on EPS could lead to a decline of about 6.58%, reflecting investor disappointment and concerns about future performance.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Southern Copper Corporation